Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Timing your meals may help maintain weight loss

NCT ID NCT05742165

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study looked at whether limiting eating to a 6- or 10-hour window each day helps adults who recently lost weight keep it off. 29 participants were randomly assigned to one of two time-restricted eating plans for 12 weeks. The goal was to see if this approach is practical and acceptable for weight loss maintenance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

29 people

The number who actually took part.

Started

Jul 2023

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥5% non-surgical weight loss from NYULH-WMP and NY-MOVE! Endocrinology Weight Management Clinic in the last 3 months * BMI between 20.5 - 45 m/kg2 * between the ages 25 to 65 years old * own a smartphone or willing to use a smartphone if provided for self-monitoring * Eating window \>12 h per day * \<150 mins/wk of physical activity * log at least 2 meals into the smartphone app on ≥5 days Exclusion Criteria: * \<25 years or \>65 years of age * Body weight in excess of 400lbs (181.4kg) * pregnant, trying to get pregnant or breastfeeding * previous or planned bariatric surgery * previous or current history of eating disorder * ongoing participation in another weight-management research study * continued participation in a weight loss program other than the proposed study * currently on appetite suppressants * currently following intermittent fasting or skipping meals * eating window \<11h 59min/day * perform overnight shift work more than once a week * work that includes travel across one or more time zones * currently on anti-obesity medications (AOMs) such as, GLP-1 analogues (exenatide, tirzepatide, semaglutide, liraglutide) and pancreatic lipase inhibitors (Orlistat/Xenical and Alli) * prescribed medications expected to result in weight loss such as Orlistat, Naltrexone, Bupropion, Lorcaserin, Phentermine, Topiramate, or Liraglutide, and who are unwilling to delay treatment with these medications for the next 3 months * unable or unwilling to provide informed consent * unable to participate meaningfully in the intervention (e.g., uncorrected sight and hearing impairment) * unwilling to accept randomization assignment * unable to log at least 2 meals into the smartphone app on ≥5 d during the screening period * have type 1 or other conditions that would preclude restricted eating windows * have type 2 diabetes with a HbA1c \>7.0% on medications except for metformin alone * narcolepsy * active cancer * organ dysfunction * current steroid use * daytime sleepiness with the Epworth Sleepiness Scale \>10 * severe insomnia with a score ≥15 on the Insomnia Severity Index * \>2.5 kg additional weight loss during run-in phase (weight regain is not an exclusion criteria)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Intermittent Fasting Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NYU Langone Health

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.